Dr. Choi has received honoraria for service on advisory boards for Takeda Pharmaceuticals, URL Pharma, Savient Pharmaceuticals, and Novartis Pharma (less than $10,000 each) and has received research funding for other projects from Takeda Pharmaceuticals.
Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008
Version of Record online: 27 SEP 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 63, Issue 10, pages 3136–3141, October 2011
How to Cite
Zhu, Y., Pandya, B. J. and Choi, H. K. (2011), Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis & Rheumatism, 63: 3136–3141. doi: 10.1002/art.30520
- Issue online: 27 SEP 2011
- Version of Record online: 27 SEP 2011
- Accepted manuscript online: 28 JUL 2011 11:33AM EST
- Manuscript Accepted: 21 JUN 2011
- Manuscript Received: 8 MAR 2011
- Takeda Pharmaceuticals International
To estimate the prevalence of gout and hyperuricemia based on the latest nationally representative sample of US men and women (National Health and Nutrition Examination Survey [NHANES] 2007–2008).
Using data from 5,707 participants in NHANES 2007–2008, we estimated the prevalence of gout and hyperuricemia. During home interviews for NHANES 2007–2008, all participants were asked about a history of health professional– or physician-diagnosed gout. Our primary definition of hyperuricemia was a serum urate level of >7.0 mg/dl for men and >5.7 mg/dl for women. We explored potential secular trends in these estimates and their possible explanations by comparing them with estimates based on 18,825 participants in NHANES-III (1988–1994).
The prevalence of gout among US adults in 2007–2008 was 3.9% (8.3 million individuals). The prevalence among men was 5.9% (6.1 million), and the prevalence among women was 2.0% (2.2 million). The mean serum urate levels were 6.14 mg/dl among men and 4.87 mg/dl among women, corresponding to hyperuricemia prevalences of 21.2% and 21.6%, respectively. These estimates were higher than those in NHANES-III, with differences of 1.2% in the prevalence of gout (95% confidence interval [95% CI] 0.6, 1.9), 0.15 mg/dl in the serum urate level (95% CI 0.07, 0.24), and 3.2% in the prevalence of hyperuricemia (95% CI 1.2, 5.2). These differences were substantially attenuated after adjusting for body mass index and/or hypertension.
These findings from nationally representative samples of US adults suggest that the prevalence of both gout and hyperuricemia remains substantial and may have increased over the past 2 decades, which is likely related to increasing frequencies of adiposity and hypertension.